Certara Inc at Barclays Global Healthcare Conference Transcript
Man.
Good afternoon everybody. I'm Luke Serga. I cover Life Science tools and diagnostics. With me today, I have John Gallagher, CFO of Sertara. Thanks again for making it. Hi Luke, thanks for having me under the bright lights here. So I guess to start off, can you just recap.
How the quarter from 4Q shook out versus what you guys were expecting and this is more of just thinking about a jump off point from.
Kind of the lumpiness and the softer demand that we saw through 25 and how the first quarter as you guys are looking at it within your assumption as to how 26 is going to progress like puts and takes as you, as you thought about it. Yeah.
Questions & Answers
Sure, thanks Luke. Glad to be here today. We finished the year in 2025 strong from a revenue and EBITDA perspective. I'll get into the bookings in a second, but, if you look at revenue. Then, organic software revenue, which was something that we're watching
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
